MXPA03001230A - Anticuerpos anti-integrina doble, composiciones y metodos de uso. - Google Patents
Anticuerpos anti-integrina doble, composiciones y metodos de uso.Info
- Publication number
- MXPA03001230A MXPA03001230A MXPA03001230A MXPA03001230A MXPA03001230A MX PA03001230 A MXPA03001230 A MX PA03001230A MX PA03001230 A MXPA03001230 A MX PA03001230A MX PA03001230 A MXPA03001230 A MX PA03001230A MX PA03001230 A MXPA03001230 A MX PA03001230A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- integrin antibodies
- dual integrin
- beta
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5029—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell motility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22336300P | 2000-08-07 | 2000-08-07 | |
US09/920,267 US7288390B2 (en) | 2000-08-07 | 2001-08-01 | Anti-dual integrin antibodies, compositions, methods and uses |
PCT/US2001/024784 WO2002012501A2 (en) | 2000-08-07 | 2001-08-07 | Anti-dual integrin antibodies, compositions, methods and uses |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA03001230A true MXPA03001230A (es) | 2004-01-29 |
Family
ID=26917697
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA03001230A MXPA03001230A (es) | 2000-08-07 | 2001-08-07 | Anticuerpos anti-integrina doble, composiciones y metodos de uso. |
Country Status (23)
Country | Link |
---|---|
US (1) | US7288390B2 (es) |
EP (2) | EP1309693B1 (es) |
JP (1) | JP5014557B2 (es) |
KR (1) | KR100832486B1 (es) |
CN (1) | CN1468307B (es) |
AT (1) | ATE470714T1 (es) |
AU (1) | AU8316701A (es) |
BR (1) | BR0113112A (es) |
CA (1) | CA2418962C (es) |
DE (1) | DE60142342D1 (es) |
DK (1) | DK1309693T3 (es) |
EA (1) | EA007617B1 (es) |
ES (1) | ES2346041T3 (es) |
HR (1) | HRP20030088B1 (es) |
HU (1) | HU229418B1 (es) |
IL (1) | IL154326A0 (es) |
MX (1) | MXPA03001230A (es) |
NO (1) | NO334999B1 (es) |
NZ (1) | NZ524146A (es) |
PL (1) | PL213030B1 (es) |
PT (1) | PT1309693E (es) |
RS (1) | RS51197B (es) |
WO (1) | WO2002012501A2 (es) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030059427A1 (en) * | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
US7163681B2 (en) * | 2000-08-07 | 2007-01-16 | Centocor, Inc. | Anti-integrin antibodies, compositions, methods and uses |
US8703126B2 (en) | 2000-10-12 | 2014-04-22 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
EP2009027B1 (en) | 2001-04-27 | 2014-05-21 | Kyowa Hakko Kirin Co., Ltd. | Anti-CD40 monoclonal antibody |
AU2002312566A1 (en) * | 2001-07-09 | 2003-01-29 | Elan Pharmaceuticals, Inc. | Methods of inhibiting amyloid toxicity |
US7829087B2 (en) * | 2001-07-09 | 2010-11-09 | Elan Pharmaceuticals, Inc. | Methods of treating cognitive impairment |
BRPI0308585B8 (pt) | 2002-03-13 | 2021-05-25 | Biogen Idec Inc | anticorpo isolado ou fragmento de ligação a antígeno do mesmo que se liga à alfavbeta6, composição, método de detecção in vitro de alfavbeta6 e construção de dna |
AR042145A1 (es) * | 2002-11-27 | 2005-06-08 | Dow Agrociences Llc | Produccion de inmunoglobulinas en plantas con una fucocilacion reducida |
PT3417875T (pt) * | 2003-02-10 | 2020-08-24 | Biogen Ma Inc | Formulação de imunoglobulinas e método de preparação das mesmas |
WO2004076488A1 (en) * | 2003-02-27 | 2004-09-10 | Theravision Gmbh | A molecule which binds cd80 and cd86 |
JP4869064B2 (ja) | 2003-04-04 | 2012-02-01 | ジェネンテック, インコーポレイテッド | 高濃度抗体及びタンパク質製剤 |
US9708410B2 (en) | 2003-05-30 | 2017-07-18 | Janssen Biotech, Inc. | Anti-tissue factor antibodies and compositions |
WO2005000871A2 (en) | 2003-06-23 | 2005-01-06 | Centocor, Inc. | Peptides antagonistic to an anti-angiogenic antibody and uses therefor |
JPWO2005068504A1 (ja) * | 2004-01-19 | 2008-01-10 | 株式会社医学生物学研究所 | 炎症性サイトカイン抑制剤 |
JP5223072B2 (ja) * | 2004-04-02 | 2013-06-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | avβ5インテグリンに関連のある疾患を治療および予防するための方法および組成物 |
AU2012216372B2 (en) * | 2004-04-02 | 2015-01-22 | The Regents Of The University Of California | Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin |
US20060008415A1 (en) * | 2004-06-25 | 2006-01-12 | Protein Design Labs, Inc. | Stable liquid and lyophilized formulation of proteins |
US20060035239A1 (en) * | 2004-08-06 | 2006-02-16 | Applera Corporation | Method and compositions for treating diseases targeting CD51 |
CA2591148A1 (en) * | 2004-12-09 | 2006-06-15 | Centocor, Inc. | Anti-integrin immunoconjugates, methods and uses |
CN102875681A (zh) | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
JP2009542810A (ja) | 2006-07-10 | 2009-12-03 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Smad4欠損癌の増殖を阻害するための組成物および方法 |
US8911964B2 (en) | 2006-09-13 | 2014-12-16 | Abbvie Inc. | Fed-batch method of making human anti-TNF-alpha antibody |
TW201516149A (zh) | 2006-09-13 | 2015-05-01 | Abbvie Inc | 細胞培養改良 |
US20090163698A1 (en) * | 2007-05-11 | 2009-06-25 | John Joseph Grigsby | Method for Preparing Antibody Conjugates |
US20090175784A1 (en) | 2007-05-11 | 2009-07-09 | Joshua Goldstein | Anti-Alpha V Immunoliposome Composition, Methods, and Uses |
US20090196913A1 (en) * | 2007-05-11 | 2009-08-06 | Ken Shi Kun Huang | Anti-Alpha-V Immunoliposome Composition, Methods, and Uses |
EP2195017B1 (en) | 2007-10-01 | 2014-10-22 | Bristol-Myers Squibb Company | Human antibodies that bind mesothelin, and uses thereof |
WO2009092011A1 (en) | 2008-01-18 | 2009-07-23 | Medimmune, Llc | Cysteine engineered antibodies for site-specific conjugation |
JP2011524741A (ja) * | 2008-05-27 | 2011-09-08 | 協和発酵キリン株式会社 | インターロイキン10受容体(il−10r)抗体及び使用方法 |
EP2373689A1 (en) | 2008-12-12 | 2011-10-12 | MedImmune, LLC | Crystals and structure of a human igg fc variant with enhanced fcrn binding |
RU2011140498A (ru) | 2009-03-06 | 2013-04-20 | Дженентек, Инк. | Препарат антител |
SG176000A1 (en) * | 2009-05-13 | 2011-12-29 | Protein Delivery Solutions Llc | Pharmaceutical system for trans-membrane delivery |
US20120213705A1 (en) | 2009-06-22 | 2012-08-23 | Medimmune, Llc | ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION |
US10087252B2 (en) | 2009-07-24 | 2018-10-02 | The Regents Of The University Of California | Methods and compositions for treating and preventing disease associated with αvβ5 integrin |
RU2545401C2 (ru) | 2010-02-23 | 2015-03-27 | Санофи | Антитела к интегрину альфа-2 и их применения |
US8993844B1 (en) | 2010-05-27 | 2015-03-31 | University Of Wyoming | Production of spider silk protein in corn |
US8906649B2 (en) | 2010-09-27 | 2014-12-09 | Janssen Biotech, Inc. | Antibodies binding human collagen II |
JP6126991B2 (ja) * | 2010-09-27 | 2017-05-10 | ヤンセン バイオテツク,インコーポレーテツド | ヒトii型コラーゲンに結合する抗体 |
CA2833477A1 (en) | 2011-04-21 | 2012-10-26 | Seattle Genetics, Inc. | Novel binder-drug conjugates (adcs) and their use |
EP2702077A2 (en) | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
EP3091029B1 (en) | 2011-10-31 | 2022-12-28 | F. Hoffmann-La Roche AG | Anti-il13 antibody formulations |
WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
EP2888287A4 (en) * | 2012-08-21 | 2016-04-20 | Ortho Clinical Diagnostics Inc | ANTIBODIES AGAINST PALIPERIDONE HAPTENES AND THEIR USE |
AU2013309506A1 (en) | 2012-09-02 | 2015-03-12 | Abbvie Inc. | Methods to control protein heterogeneity |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
SG11201507230PA (en) | 2013-03-12 | 2015-10-29 | Abbvie Inc | Human antibodies that bind human tnf-alpha and methods of preparing the same |
WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
WO2014159579A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE |
US10035859B2 (en) | 2013-03-15 | 2018-07-31 | Biogen Ma Inc. | Anti-alpha V beta 6 antibodies and uses thereof |
CN105392801A (zh) * | 2013-03-15 | 2016-03-09 | 比奥根Ma公司 | 使用抗αvβ5抗体治疗和预防急性肾损伤 |
WO2014143739A2 (en) | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Anti-alpha v beta 6 antibodies and uses thereof |
EP3052640A2 (en) | 2013-10-04 | 2016-08-10 | AbbVie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
BR112016014830A2 (pt) | 2013-12-23 | 2017-09-19 | Bayer Pharma AG | Conjugados de fármaco de anticorpo (adcs) com inibidores de ksp |
MX2017003014A (es) * | 2014-09-12 | 2017-05-30 | Biogen Ma Inc | Anticuerpos anti-alfa v beta 5 humanizados y usos de estos. |
US10435472B2 (en) | 2014-09-17 | 2019-10-08 | Merck Patent Gmbh | Method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases |
EP3193927B1 (en) | 2014-09-17 | 2020-11-25 | Merck Patent GmbH | A method of treating solid cancers and/or metastases thereof, medicaments therefore, and a method of predicting the clinical outcome of treating solid cancers and/or metastases thereof |
AU2016282723B2 (en) | 2015-06-22 | 2021-09-23 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (ADCs) and antibody prodrug conjugates (APDCs) with enzymatically cleavable groups |
CN106630490A (zh) * | 2015-07-26 | 2017-05-10 | 李娜 | 一种去除含镉污水污染物的方法 |
WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
CN108697791B (zh) * | 2015-11-03 | 2022-08-23 | 詹森生物科技公司 | 特异性结合pd-1的抗体及其用途 |
BR112018012352A2 (pt) * | 2015-12-16 | 2018-12-11 | Merck Sharp & Dohme Corp. | anticorpos anti-lag3 e fragmentos de ligação ao antígeno |
EP3207937A1 (en) * | 2016-02-17 | 2017-08-23 | Royal College of Surgeons in Ireland | A method of treating or preventing sepsis |
JP7251981B2 (ja) | 2016-03-24 | 2023-04-04 | バイエル ファーマ アクチエンゲゼルシャフト | 酵素開裂基を有する細胞毒性活性剤のプロドラッグ |
EP3471776B1 (en) | 2016-06-15 | 2022-05-04 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates with ksp inhibitors and anti-cd123-antibodies |
CN106265480A (zh) * | 2016-09-03 | 2017-01-04 | 山西纳安生物科技有限公司 | 纳米抗体阴道给药系统及制备方法和应用 |
JP7030811B2 (ja) | 2016-12-21 | 2022-03-07 | バイエル・ファルマ・アクティエンゲゼルシャフト | Ksp阻害剤を有する特異的抗体-薬物コンジュゲート(adc) |
JP7066714B2 (ja) | 2016-12-21 | 2022-05-13 | バイエル・ファルマ・アクティエンゲゼルシャフト | 酵素的に切断可能な基を有する抗体薬物コンジュゲート(adc) |
US20190351066A1 (en) | 2016-12-21 | 2019-11-21 | Bayer Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
CN114901700A (zh) * | 2019-11-21 | 2022-08-12 | 尤尼蒂生物技术公司 | 针对tie-2的抗体及其使用方法 |
Family Cites Families (184)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4309989A (en) | 1976-02-09 | 1982-01-12 | The Curators Of The University Of Missouri | Topical application of medication by ultrasound with coupling agent |
FR2374910A1 (fr) | 1976-10-23 | 1978-07-21 | Choay Sa | Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
US5149636A (en) | 1982-03-15 | 1992-09-22 | Trustees Of Columbia University In The City Of New York | Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8426467D0 (en) | 1984-10-19 | 1984-11-28 | Technology Licence Co Ltd | Monoclonal antibodies |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
GB2183661B (en) | 1985-03-30 | 1989-06-28 | Marc Ballivet | Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique |
SE448277B (sv) | 1985-04-12 | 1987-02-09 | Draco Ab | Indikeringsanordning vid en doseringsanordning for lekemedel |
US4766067A (en) | 1985-05-31 | 1988-08-23 | President And Fellows Of Harvard College | Gene amplification |
US4870163A (en) | 1985-08-29 | 1989-09-26 | New York Blood Center, Inc. | Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5576195A (en) | 1985-11-01 | 1996-11-19 | Xoma Corporation | Vectors with pectate lyase signal sequence |
US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
DE3600905A1 (de) | 1986-01-15 | 1987-07-16 | Ant Nachrichtentech | Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
SE453566B (sv) | 1986-03-07 | 1988-02-15 | Draco Ab | Anordning vid pulverinhalatorer |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4767402A (en) | 1986-07-08 | 1988-08-30 | Massachusetts Institute Of Technology | Ultrasound enhancement of transdermal drug delivery |
US4925673A (en) | 1986-08-18 | 1990-05-15 | Clinical Technologies Associates, Inc. | Delivery systems for pharmacological agents encapsulated with proteinoids |
US4889818A (en) | 1986-08-22 | 1989-12-26 | Cetus Corporation | Purified thermostable enzyme |
US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
DE3631229A1 (de) | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
IL83419A0 (en) | 1986-09-15 | 1988-01-31 | Westinghouse Electric Corp | Antibodies reactive with chlorinated phenols,their preparation and their use |
US4921794A (en) | 1987-01-14 | 1990-05-01 | President And Fellows Of Harvard College | T7 DNA polymerase |
US4795699A (en) | 1987-01-14 | 1989-01-03 | President And Fellows Of Harvard College | T7 DNA polymerase |
EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
ATE114723T1 (de) | 1987-03-02 | 1994-12-15 | Enzon Lab Inc | Organismus als träger für ''single chain antibody domain (scad)''. |
EP0288088B1 (en) | 1987-04-24 | 1994-03-09 | Teijin Limited | Detection of tumor necrosis factor; monoclonal antibody and kit |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
CA1341235C (en) | 1987-07-24 | 2001-05-22 | Randy R. Robinson | Modular assembly of antibody genes, antibodies prepared thereby and use |
US4939666A (en) | 1987-09-02 | 1990-07-03 | Genex Corporation | Incremental macromolecule construction methods |
EP0396612B1 (en) | 1988-01-11 | 1996-07-24 | Xoma Corporation | Novel plasmid vector with pectate lyase signal sequence |
US6010902A (en) | 1988-04-04 | 2000-01-04 | Bristol-Meyers Squibb Company | Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity |
US4956288A (en) | 1988-04-22 | 1990-09-11 | Biogen, Inc. | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA |
US5130238A (en) | 1988-06-24 | 1992-07-14 | Cangene Corporation | Enhanced nucleic acid amplification process |
US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5091310A (en) | 1988-09-23 | 1992-02-25 | Cetus Corporation | Structure-independent dna amplification by the polymerase chain reaction |
US5066584A (en) | 1988-09-23 | 1991-11-19 | Cetus Corporation | Methods for generating single stranded dna by the polymerase chain reaction |
US5142033A (en) | 1988-09-23 | 1992-08-25 | Hoffmann-La Roche Inc. | Structure-independent DNA amplification by the polymerase chain reaction |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
JP2919890B2 (ja) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用 |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US4994370A (en) | 1989-01-03 | 1991-02-19 | The United States Of America As Represented By The Department Of Health And Human Services | DNA amplification technique |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5266491A (en) | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
DE3909708A1 (de) | 1989-03-23 | 1990-09-27 | Boehringer Mannheim Gmbh | Verfahren zur herstellung bispezifischer antikoerper |
AU652539B2 (en) | 1989-05-16 | 1994-09-01 | Medical Research Council | Co-expression of heteromeric receptors |
CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
CA2016841C (en) | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
EP0739904A1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
AU640400B2 (en) | 1989-08-07 | 1993-08-26 | Peptide Technology Ltd. | Tumour necrosis factor binding ligands |
AU638762B2 (en) | 1989-10-05 | 1993-07-08 | Optein Inc | Cell-free synthesis and isolation of novel genes and polypeptides |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
TW212184B (es) | 1990-04-02 | 1993-09-01 | Takeda Pharm Industry Co Ltd | |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
DK0600866T3 (da) | 1990-06-01 | 1998-03-09 | Chiron Corp | Præparater og fremgangsmåder til identifikation af biologisk aktive molekyler |
US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
EP0547065B1 (en) | 1990-06-29 | 2001-08-29 | Large Scale Biology Corporation | Melanin production by transformed microorganisms |
US5580734A (en) | 1990-07-13 | 1996-12-03 | Transkaryotic Therapies, Inc. | Method of producing a physical map contigous DNA sequences |
WO1992002551A1 (en) | 1990-08-02 | 1992-02-20 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5877397A (en) * | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
DK0814159T3 (da) | 1990-08-29 | 2005-10-24 | Genpharm Int | Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
WO1992005258A1 (en) | 1990-09-20 | 1992-04-02 | La Trobe University | Gene encoding barley enzyme |
GB9022648D0 (en) | 1990-10-18 | 1990-11-28 | Charing Cross Sunley Research | Polypeptide and its use |
AU8727291A (en) | 1990-10-29 | 1992-06-11 | Cetus Oncology Corporation | Bispecific antibodies, method of production, and uses thereof |
WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
US5582996A (en) | 1990-12-04 | 1996-12-10 | The Wistar Institute Of Anatomy & Biology | Bifunctional antibodies and method of preparing same |
CA2104698A1 (en) | 1991-02-21 | 1992-08-22 | John J. Toole | Aptamers specific for biomolecules and methods of making |
US5404871A (en) | 1991-03-05 | 1995-04-11 | Aradigm | Delivery of aerosol medications for inspiration |
EP0575545B1 (en) | 1991-03-15 | 2003-05-21 | Amgen Inc. | Pegylation of polypeptides |
DK1471142T3 (da) | 1991-04-10 | 2009-03-09 | Scripps Research Inst | Heterodimere receptor-biblioteker under anvendelse af fagemider |
DE4118120A1 (de) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
ATE359842T1 (de) | 1991-07-02 | 2007-05-15 | Nektar Therapeutics | Abgabevorrichtung für nebelförmige medikamente |
US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
US5733761A (en) | 1991-11-05 | 1998-03-31 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
ATE463573T1 (de) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
CA2103887C (en) | 1991-12-13 | 2005-08-30 | Gary M. Studnicka | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
DE4207475A1 (de) | 1992-03-10 | 1993-09-16 | Goldwell Ag | Mittel zum blondieren von menschlichen haaren und verfahren zu dessen herstellung |
US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
DE69322860T2 (de) | 1992-04-03 | 1999-07-01 | Genentech Inc | Antikörper gegen alpha v beta 3 integrin |
AU4829593A (en) | 1992-09-23 | 1994-04-12 | Fisons Plc | Inhalation device |
WO1994008038A1 (en) | 1992-10-02 | 1994-04-14 | Trustees Of Dartmouth College | Bispecific reagents for redirected targeting of low density lipoprotein |
ATE174804T1 (de) | 1992-10-19 | 1999-01-15 | Dura Pharma Inc | Trockenpulverinhalator |
US5643252A (en) | 1992-10-28 | 1997-07-01 | Venisect, Inc. | Laser perforator |
AU5670194A (en) | 1992-11-20 | 1994-06-22 | Enzon, Inc. | Linker for linked fusion polypeptides |
AU675689B2 (en) | 1992-12-01 | 1997-02-13 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
US5849695A (en) | 1993-01-13 | 1998-12-15 | The Regents Of The University Of California | Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals |
DK0680451T3 (da) | 1993-01-19 | 1999-07-19 | Glaxo Group Ltd | Aerosoldispenser samt fremgangsmåde ved dens fremstilling |
CA2155728C (en) | 1993-02-12 | 2000-04-25 | Gerald R. Crabtree | Regulated transcription of targeted genes and other biological events |
US5770428A (en) | 1993-02-17 | 1998-06-23 | Wisconsin Alumni Research Foundation | Chimeric retrovial expression vectors and particles containing a simple retroviral long terminal repeat, BLV or HIV coding regions and cis-acting regulatory sequences, and an RNA translational enhancer with internal ribsome entry site |
EP0614989A1 (en) | 1993-02-17 | 1994-09-14 | MorphoSys AG | A method for in vivo selection of ligand-binding proteins |
EP0754225A4 (en) | 1993-04-26 | 2001-01-31 | Genpharm Int | HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS |
US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
DE4337197C1 (de) | 1993-10-30 | 1994-08-25 | Biotest Pharma Gmbh | Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore |
US5814599A (en) | 1995-08-04 | 1998-09-29 | Massachusetts Insitiute Of Technology | Transdermal delivery of encapsulated drugs |
SE9304060D0 (sv) | 1993-12-06 | 1993-12-06 | Bioinvent Int Ab | Sätt att selektera specifika bakteriofager |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
JPH09510201A (ja) | 1994-03-07 | 1997-10-14 | メダレツクス・インコーポレーテツド | 臨床的効用を有する二重特異性分子 |
US5753230A (en) | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
US5763733A (en) | 1994-10-13 | 1998-06-09 | Enzon, Inc. | Antigen-binding fusion proteins |
DE69531187T2 (de) | 1994-12-20 | 2004-04-22 | Merck Patent Gmbh | Monoklonaler Antikörper gegen das Alpha-V-Integrin |
US5549551A (en) | 1994-12-22 | 1996-08-27 | Advanced Cardiovascular Systems, Inc. | Adjustable length balloon catheter |
US5674483A (en) * | 1995-01-31 | 1997-10-07 | National Jewish Medical And Research Center | Treatment for diseases involving inflammation |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US6037453A (en) | 1995-03-15 | 2000-03-14 | Genentech, Inc. | Immunoglobulin variants |
US5656730A (en) | 1995-04-07 | 1997-08-12 | Enzon, Inc. | Stabilized monomeric protein compositions |
EP0822830B1 (en) * | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
SK18898A3 (en) | 1995-08-14 | 1998-07-08 | Scripps Research Inst | Method compositions useful for inhibition of 'alpha'v'beta'5 mediated angiogenesis |
US20030009404A2 (en) * | 1995-10-12 | 2003-01-09 | Mopex, Inc. | Open end mutual fund securitization process |
GB9526100D0 (en) | 1995-12-20 | 1996-02-21 | Intersurgical Ltd | Nebulizer |
EA001016B1 (ru) | 1996-01-03 | 2000-08-28 | Глаксо Груп Лимитед | Ингаляционное устройство |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
DE69710319T2 (de) | 1996-03-29 | 2002-08-14 | Searle & Co | Para-substituierte phenylpropansäure derivate als integrin-antagonisten |
DE19624387C2 (de) | 1996-06-19 | 1999-08-19 | Hatz Motoren | Kaltstartvorrichtung |
ATE210682T1 (de) | 1996-09-03 | 2001-12-15 | Gsf Forschungszentrum Umwelt | Zerstörung von kontaminierenden tumorzellen in stammzelltransplantaten mit bispezifischen antikörpern |
JP4044648B2 (ja) | 1996-10-04 | 2008-02-06 | 日本エンバイロケミカルズ株式会社 | 洗剤またはその分解物の免疫学的分析用モノクローナル抗体およびその用途 |
CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
US20010011125A1 (en) * | 1997-01-30 | 2001-08-02 | William D. Huse | Anti-alpha v beta 3 recombinant human antibodies, nucleic acids encoding same and methods of use |
US5879681A (en) | 1997-02-07 | 1999-03-09 | Emisphere Technolgies Inc. | Compounds and compositions for delivering active agents |
US5921447A (en) | 1997-02-13 | 1999-07-13 | Glaxo Wellcome Inc. | Flow-through metered aerosol dispensing apparatus and method of use thereof |
AU6954398A (en) * | 1997-04-11 | 1998-11-11 | G.D. Searle & Co. | Antagonistic anti-avb3 integrin antibodies |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
IL120943A (en) | 1997-05-29 | 2004-03-28 | Univ Ben Gurion | A system for administering drugs through the skin |
US6160099A (en) | 1998-11-24 | 2000-12-12 | Jonak; Zdenka Ludmila | Anti-human αv β3 and αv β5 antibodies |
US6521593B1 (en) | 1999-02-01 | 2003-02-18 | Childrens Hospital Los Angeles | Methods for inhibiting brain tumor growth |
US6342221B1 (en) * | 1999-04-28 | 2002-01-29 | Board Of Regents, The University Of Texas System | Antibody conjugate compositions for selectively inhibiting VEGF |
US6175824B1 (en) * | 1999-07-14 | 2001-01-16 | Chi Research, Inc. | Method and apparatus for choosing a stock portfolio, based on patent indicators |
US7184981B2 (en) * | 1999-12-06 | 2007-02-27 | X/Net Associates, Inc. | Method and system for the creation of a class of loan securities |
US6484152B1 (en) * | 1999-12-29 | 2002-11-19 | Optimumportfolio.Com, Llc | Automated portfolio selection system |
US6604113B1 (en) * | 2000-04-14 | 2003-08-05 | Qwest Communications International, Inc. | Method and apparatus for providing account information |
US20020059126A1 (en) * | 2000-06-27 | 2002-05-16 | John Ricciardi | System and method for a selecting an investment item |
US20030093353A1 (en) * | 2000-07-05 | 2003-05-15 | Marketocracy | System and method for creating and maintaining investment portfolios |
JP2004527029A (ja) * | 2001-02-06 | 2004-09-02 | ストレイテジック キャピタル ネットワーク エルエルシー | 投資の選択を容易にするシステム |
WO2002089033A1 (en) * | 2001-04-30 | 2002-11-07 | Philip Tan Meng Ngee | A multi-dimensional method and system of simulating and managing an alliance investment portfolio |
US20030036945A1 (en) * | 2001-05-22 | 2003-02-20 | Del Vecchio Joseph Nicholas | System, method and computer program product for assessing the value of intellectual property |
US20020178099A1 (en) * | 2001-05-25 | 2002-11-28 | Shayne Young | Methods and systems for managing a portfolio of securities |
US7509278B2 (en) * | 2001-07-16 | 2009-03-24 | Jones W Richard | Long-term investing |
US7512555B2 (en) * | 2001-11-13 | 2009-03-31 | Gregory M Finn | Investment management tool |
US20030143603A1 (en) * | 2001-11-30 | 2003-07-31 | Jill Giles-Komar | Anti-TNF antibodies, compositions, methods and uses |
US20040002892A1 (en) * | 2002-03-20 | 2004-01-01 | Martin Gluck | Portal for global portfolio management system method & apparatus |
US7433839B2 (en) * | 2002-03-20 | 2008-10-07 | Bodurtha Stephen G | Total return asset contracts and associated processing systems |
CA2381689A1 (en) * | 2002-04-12 | 2003-10-12 | Algorithmics International Corp. | System, method and framework for generating scenarios |
US20040024673A1 (en) * | 2002-07-31 | 2004-02-05 | International Business Machines Corporation | Method for optimizing the allocation of resources based on market and technology considerations |
US7606756B2 (en) * | 2002-08-02 | 2009-10-20 | Jpmorgan Chase Bank, N.A. | Synthetic funds having structured notes |
US20040111350A1 (en) * | 2002-08-14 | 2004-06-10 | Water Street Advisers, Inc. | Process to create market-sector investment portfolio performance indices |
US7340425B2 (en) * | 2002-10-29 | 2008-03-04 | First Trust Portfolios, L.P. | Method for generating a portfolio of stocks |
US8121889B2 (en) * | 2003-05-16 | 2012-02-21 | International Business Machines Corporation | Information technology portfolio management |
US20050267835A1 (en) * | 2003-12-31 | 2005-12-01 | Scott Condron | System and method for evaluating exposure across a group of investment portfolios by category |
US20050251465A1 (en) * | 2004-05-02 | 2005-11-10 | Brown Daniel P | System and method for structuring and operating an investment vehicle |
US7739183B2 (en) * | 2004-06-03 | 2010-06-15 | Voudrie Jeffrey D | Real-time client portfolio management system |
US8442889B2 (en) * | 2004-07-12 | 2013-05-14 | Darrin B. Farrow | Asset allocation based system for individual investor portfolio selection |
US20060031149A1 (en) * | 2004-08-04 | 2006-02-09 | Lyons Timothy J | Investment vehicle and methods and systems for implementing investment strategy |
TWI503850B (zh) | 2013-03-22 | 2015-10-11 | Polytronics Technology Corp | 過電流保護元件 |
-
2001
- 2001-08-01 US US09/920,267 patent/US7288390B2/en not_active Expired - Fee Related
- 2001-08-07 AT AT01961945T patent/ATE470714T1/de active
- 2001-08-07 DK DK01961945.1T patent/DK1309693T3/da active
- 2001-08-07 CA CA2418962A patent/CA2418962C/en not_active Expired - Fee Related
- 2001-08-07 EP EP01961945A patent/EP1309693B1/en not_active Expired - Lifetime
- 2001-08-07 IL IL15432601A patent/IL154326A0/xx not_active IP Right Cessation
- 2001-08-07 WO PCT/US2001/024784 patent/WO2002012501A2/en active IP Right Grant
- 2001-08-07 AU AU8316701A patent/AU8316701A/xx active Pending
- 2001-08-07 EA EA200300244A patent/EA007617B1/ru not_active IP Right Cessation
- 2001-08-07 RS YUP-94/03A patent/RS51197B/sr unknown
- 2001-08-07 DE DE60142342T patent/DE60142342D1/de not_active Expired - Lifetime
- 2001-08-07 MX MXPA03001230A patent/MXPA03001230A/es active IP Right Grant
- 2001-08-07 PL PL366211A patent/PL213030B1/pl unknown
- 2001-08-07 PT PT01961945T patent/PT1309693E/pt unknown
- 2001-08-07 BR BR0113112-5A patent/BR0113112A/pt not_active Application Discontinuation
- 2001-08-07 NZ NZ524146A patent/NZ524146A/en not_active IP Right Cessation
- 2001-08-07 EP EP10165270A patent/EP2253646A1/en not_active Withdrawn
- 2001-08-07 KR KR1020037001834A patent/KR100832486B1/ko not_active IP Right Cessation
- 2001-08-07 HU HU0302128A patent/HU229418B1/hu not_active IP Right Cessation
- 2001-08-07 ES ES01961945T patent/ES2346041T3/es not_active Expired - Lifetime
- 2001-08-07 JP JP2002517789A patent/JP5014557B2/ja not_active Expired - Fee Related
- 2001-08-07 CN CN018169384A patent/CN1468307B/zh not_active Expired - Fee Related
-
2003
- 2003-02-07 HR HRP20030088AA patent/HRP20030088B1/hr not_active IP Right Cessation
- 2003-02-07 NO NO20030621A patent/NO334999B1/no not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL154326A0 (en) | Anti-dual integrin antibodies, compositions, methods and uses | |
CY2019029I2 (el) | Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις | |
WO1997046589A3 (en) | Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods | |
DE69808609D1 (de) | Antagonistische anti-avb3 integrin antikörper | |
IS8950A (is) | Einklóna mótefni gegn CTLA-4 úr manni. | |
RS53984B1 (en) | IP-10 ANTIBODIES AND THEIR USES | |
IL158643A (en) | Anti-hmg monoclonal antibodies and compositions containing the same | |
GB0029360D0 (en) | Humanised antibodies and uses thereof | |
IL147517A0 (en) | Monoclonal antibodies and immunoassay utilizing the same | |
EP1178829A4 (en) | HUMAN MONOCLONAL ANTIBODY | |
EP1354896A4 (en) | NEW MONOCLONAL ANTIBODY | |
HUP0300142A3 (en) | Monoclonal antibodies specific to the human ldl receptor, their production and use | |
IL139852A0 (en) | Monoclonal antibodies directed against the g3bp protein, and uses | |
EP0759943A4 (en) | MONOCLONAL ANTIBODIES SPECIFIC TO AN ENDOGLYX-1 ANTIGEN OF VASCULAR ENDOTHELIAL CELLS, THE ANTIGEN ITSELF AND USES THEREOF | |
BR9702101A (pt) | Hibridoma e anticorpo monoclonal | |
ZA986064B (en) | Ancrod-specific monoclonal antibodies, antibody fragments, mixtures or derivatives thereof and their use. | |
IL94304A0 (en) | Novel tumor-associated antigen,antibodies,compositions and uses therefor | |
ZA99319B (en) | Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies and uses of same. | |
IL135025A0 (en) | Monoclonal antibodies to the human ldl receptor, their production and use | |
ZA200200730B (en) | Human monoclonal antibodies to prostate specific membrane antigen. | |
GB0016824D0 (en) | Human monoclonal antibodies | |
GB0017139D0 (en) | Human monoclonal antibodies | |
GB0029846D0 (en) | Monoclonal antibody | |
GB0030139D0 (en) | Monoclonal antibody |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |